Tsujisaki M, Imai K, Tokuchi S, Hanzawa Y, Ishida T, Kitagawa H, Hinoda Y, Yachi A
Department of Internal Medicine (Section 1), Sapporo Medical College, Japan.
Cancer Res. 1991 May 15;51(10):2599-604.
Anti-idiotypic monoclonal antibodies (MoAbs) were prepared in a syngeneic system against anti-carcinoembryonic antigen (CEA) MoAb 5B3 (IgG1), which reacted with a carbohydrate moiety on CEA, and MoAb MA208 (IgG1), which reacted with a peptide on CEA. Anti-idiotypic MoAb T3-503 and T4-202 recognized the private idiotype of MoAb 5B3; anti-idiotypic MoAb M7-049 and M7-625 did so for MoAb MA208. Idiotype mapping showed that MoAb 5B3 has at least two distinct idiotopes at its combining site and MoAb MA208 also has two. Four different anti-idiotypic MoAbs (Ab2) could induce anti-anti-idiotypic antibodies (Ab3) specific to their respective immunizing anti-idiotypic MoAbs. Anti-anti-idiotypic MoAb M7-625 antiserum (at least a part of the antibodies) have the same reactivity as MoAb MA208, since the serum competed with the binding of MoAb MA208 against CEA and contained the antibody population reactive with purified CEA in immunoblotting assay. These results suggest that anti-idiotypic MoAb M7-625 bears the internal image of the antigen (CEA) and induces the anti-anti-idiotypic antibodies specific to CEA. Therefore, an anti-idiotypic antibody bearing the internal image of a tumor associated antigen might be used as a possible tool for vaccination or immunotherapy against malignant tumors as an antigen specific immunomodulator.
抗独特型单克隆抗体（MoAbs）是在同基因系统中针对抗癌胚抗原（CEA）单克隆抗体5B3（IgG1）制备的，该抗体与CEA上的碳水化合物部分发生反应，以及单克隆抗体MA208（IgG1），其与CEA上的肽发生反应。抗独特型单克隆抗体T3 - 503和T4 - 202识别单克隆抗体5B3的独特型；抗独特型单克隆抗体M7 - 049和M7 - 625则针对单克隆抗体MA208识别其独特型。独特型图谱显示，单克隆抗体5B3在其结合位点至少有两个不同的独特位，单克隆抗体MA208也有两个。四种不同的抗独特型单克隆抗体（Ab2）可以诱导针对各自免疫的抗独特型单克隆抗体的抗抗独特型抗体（Ab3）。抗抗独特型单克隆抗体M7 - 625抗血清（至少部分抗体）具有与单克隆抗体MA208相同的反应性，因为该血清与单克隆抗体MA208与CEA的结合发生竞争，并且在免疫印迹分析中含有与纯化的CEA反应的抗体群体。这些结果表明，抗独特型单克隆抗体M7 - 625具有抗原（CEA）的内影像，并诱导针对CEA的抗抗独特型抗体。因此，具有肿瘤相关抗原内影像的抗独特型抗体可能作为一种可能的工具，作为抗原特异性免疫调节剂用于针对恶性肿瘤的疫苗接种或免疫治疗。
